Allorion Therapeutics (Allorion) has entered into an exclusive option and global license agreement with AstraZeneca to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC). Under the terms of the agreement, AstraZeneca will be granted an exclusive option to license a novel EGFR L858R allosteric inhibitor to develop and commercialize globally. Allorion is eligible to receive upfront and near-term payments of up to $40 million, and additional development and commercial milestone payments of over $500 million, as well as tiered royalties on net sales worldwide.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,106 GBX | +0.72% |
|
-1.80% | +14.21% |
07-04 | ASTRAZENECA : Goldman Sachs maintains a Buy rating | ZD |
07-03 | ASTRAZENECA : Buy rating from Berenberg | ZD |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.21% | 238B | |
+54.07% | 809B | |
+38.95% | 621B | |
-7.05% | 351B | |
+15.44% | 319B | |
+5.72% | 289B | |
-0.45% | 221B | |
+14.58% | 218B | |
+7.42% | 166B | |
-3.79% | 157B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca